172 related articles for article (PubMed ID: 12194534)
1. Population pharmacokinetic analysis of the major metabolites of capecitabine.
Gieschke R; Reigner B; Blesch KS; Steimer JL
J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
[TBL] [Abstract][Full Text] [Related]
2. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Urien S; Rezaí K; Lokiec F
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
Desmoulin F; Gilard V; Malet-Martino M; Martino R
Drug Metab Dispos; 2002 Nov; 30(11):1221-9. PubMed ID: 12386128
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
Inaishi T; Fujita KI; Matsumoto N; Shimokata T; Maeda O; Kikumori T; Hattori N; Nakayama G; Ando Y
In Vivo; 2020; 34(6):3539-3544. PubMed ID: 33144465
[TBL] [Abstract][Full Text] [Related]
13. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
Lunar N; Etienne-Grimaldi MC; Macaire P; Thomas F; Dalenc F; Ferrero JM; Pivot X; Milano G; Royer B; Schmitt A
Cancer Chemother Pharmacol; 2021 Feb; 87(2):229-239. PubMed ID: 33386926
[TBL] [Abstract][Full Text] [Related]
16. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
[TBL] [Abstract][Full Text] [Related]
17. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
[TBL] [Abstract][Full Text] [Related]
18. [Discovery and development of novel anticancer drug capecitabine].
Ishitsuka H; Shimma N; Horii I
Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
[TBL] [Abstract][Full Text] [Related]
19. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
